SCHEMBL2383010

SCHEMBL2383010

CC(O)(c1ccccc1)c1cccc(O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 4/20 0.47
ESR2 Q92731 4/20 0.47
CYP3A4 P08684 3/20 0.47
ALDH1A1 P00352 3/20 0.47
KIF11 P52732 7/20 0.45
CA12 O43570 2/20 0.44
CA2 P00918 2/20 0.44
CA9 Q16790 2/20 0.44
CA14 Q9ULX7 2/20 0.44
LMNA P02545 1/20 0.44
CA5A P35218 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CA5B Q9Y2D0 1/20 0.44
HSD17B1 P14061 2/20 0.42
HSD17B2 P37059 2/20 0.42
ACHE P22303 1/20 0.41
TSHR P16473 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CA1 P00915 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11432364 0.87 KMT2A (0.46) ESR1ESR2CYP3A4ALDH1A1HSD17B10
SCHEMBL2384717 0.86 KIF11 (0.50) ESR1ESR2CYP3A4ALDH1A1KIF11
SCHEMBL2383037 0.84 ACHE (0.59) ESR1ESR2CYP3A4ALDH1A1KIF11
SCHEMBL249404 0.82 KMT2A (0.55) ESR1ESR2CYP3A4ALDH1A1HSD17B10
Phenol SCHEMBL7192832 0.81 ALDH1A1 (0.54) ESR1ESR2CYP3A4ALDH1A1KIF11
SCHEMBL29459449 0.81 ESR1 (0.67) ESR1ESR2CYP3A4ALDH1A1KIF11
SCHEMBL4924552 0.81 ESR1 (0.65) ESR1ESR2CYP3A4ALDH1A1KIF11
SCHEMBL50818 0.81 ESR1 (0.67) ESR1ESR2CYP3A4ALDH1A1KIF11
SCHEMBL29943758 0.80 ALDH1A1 (0.50) ESR1ESR2CYP3A4ALDH1A1KIF11
SCHEMBL9326685 0.80 ESR2 (0.71) ESR1ESR2CYP3A4ALDH1A1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293715-B2 10a-Azalide compound crosslinked at 10a- and 12-positions TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-09-29 US disclosed
EP-2177526-A1 10A-AZALIDE COMPOUND CROSSLINKED AT POSITION-10A AND POSITION-12 Taisho Pharmaceutical Co. Ltd. (JP) 2010-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS DCLRE1A, AZI2, CHD9 ESR1 2982/4885ESR2 2732/4885CYP3A4 1260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.